Boehringer Ingelheim Venture Fund

Corporate venture fund established in 2010 that invests in first-in-class, disease-modifying therapeutics across modalities. The fund is globally active in the EU, US and China and focuses on early-stage company formation and Seed/Series A investments aligned with Boehringer Ingelheim's strategic interests.